Kestrel Therapeutics received FDA investigational new drug clearance for KST‑6051, a novel oral pan‑KRAS inhibitor, enabling the FALCON first‑in‑human phase I trial to start by quarter end. The move advances a small‑molecule approach targeting KRAS‑driven cancers, an area of sustained industry focus. Separately, Great Novel Therapeutics Biotech & Medicals Corp. secured FDA IND clearance for GNTbm‑38, an epigenetic immunoactivator slated for a phase I trial in advanced solid tumors and relapsed/refractory peripheral T‑cell lymphoma. The asset targets epigenetic pathways to stimulate antitumor immunity. These regulatory greenlights highlight continued momentum for early‑stage oncology programs across targeted small molecules and epigenetic immunotherapies.